{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-229043","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2022-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.481427+00:00","generated_at":"2026-06-23T21:21:39.238371+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CEO Quinn departs; interim CEO Kastenmayer named; restructuring cuts headcount 25%, prioritizes AGLE-177","bullets":["CEO Anthony Quinn departed Aug 24, 2022 via mutual agreement; no disagreement; to serve as R&D Advisor then consultant through Sept 2023.","James Kastenmayer (General Counsel) appointed Interim CEO; base salary raised to $588,000, target bonus set at 50%.","Michael Hanley promoted to Chief Business Officer from Chief Commercial Officer.","Restructuring reduces headcount ~25% YTD; transitions patients out of pegzilarginase extension studies in Arginase 1 Deficiency.","Company prioritizes AGLE-177 development; expects cash runway extended into Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-229043","json":"https://secwatch.observer/filing/0001193125-22-229043.json","markdown":"https://secwatch.observer/filing/0001193125-22-229043.md","text":"https://secwatch.observer/filing/0001193125-22-229043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522229043/0001193125-22-229043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522229043/d253845d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:21:39.238371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0965a63d8e","claim":"Anthony Quinn changed role as President and Chief Executive Officer at Spyre Therapeutics, Inc..","evidence_excerpt":"Dr. Quinn ceased his role as the Company’s President and Chief Executive Officer, effective August 24, 2022 (the “CEO Transition Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522229043/0001193125-22-229043-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased his role as"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"565319a6ff","claim":"James Kastenmayer was appointed as Interim Chief Executive Officer at Spyre Therapeutics, Inc..","evidence_excerpt":"Effective as of the Transition Date, the Board appointed James Kastenmayer, the Company’s General Counsel and Corporate Secretary, to succeed Dr. Quinn as Interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522229043/0001193125-22-229043-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}